Tagged with M&A

Tunisia Sara Masmoudi, general manager at Teriak, one of Tunisia’s top three pharmaceutical companies, sums up the evolution the company has undergone since she took over its direction in 2003 at age 32. She also talks about the recent acquisition Teriak has made of Cinpharm, a Cameroonian manufacturer, in line with…

Austria Dr. Wolfgang Schnitzel, general manager of Shire Austria, and Karl-Heinz Hofbauer, site lead Vienna and managing director for the Technical Operations business, discuss the huge impact of Shire’s 32 billion USD acquisition of Baxalta that has grown the workforce from a few Shire employees in Austria to 3,500. Furthermore, they…

Canada Jonathan Ross Goodman, founder and CEO of Knight Therapeutics Inc., discusses the unique backstory behind the founding of the company, coming on the heels of the sale of Paladin Labs Inc., his previous company, for CAD 3.2 billion, the cycling accident that left him brain-damaged but more committed than ever…

Colombia Carlos Alberto Florez, newly appointed general manager of Aspen Colombia, already has a very clear view on Aspen’s strategic direction, discussing the expansion of the infant nutrition segment and the recent acquisition of anaesthetics lines. He also underlines his passion for start-up businesses and his eagerness to see Aspen evolve…

Colombia Javier Castro of Boehringer Ingelheim (BI) Colombia has been mandated to integrate Sanofi’s animal healthcare business into BI’s operation and prepare the Colombian affiliate for the coming changes in the market. He discusses the importance of embracing change, the animal healthcare business potential in Colombia and his desire to be…

Hong Kong Described as the first unicorn [a startup company valued at over USD 1 billion] of Hong Kong, Cirina has recently merged with Grail to further improve detection of cancer at its early stage. Pharmaboardroom sat down with Professor Denis Lo, the man behind Cirina’s technology, to further discuss his groundbreaking…

Switzerland EY’s Biotech Team Leader for the EMEIA region discusses the challenges Europe’s fragmented capital markets pose for biotech startups, the under-communicated benefits of doing an IPO on the Swiss stock exchange and the implications of the Actelion acquisition for the wider Swiss life sciences ecosystem. Among other things, you are…

Switzerland “Get it done! That is what CARBOGEN AMCIS is all about!” – The CEO of the Swiss drug development and commercialization services company elaborates on the company’s strong mindset and declares customer intimacy to be their unique selling point. CARBOGEN AMCIS celebrated its 10th year since joining the Dishman group.…

Switzerland Backed by the Japanese Zeria Group, fast growing gastrointestinal (GI) specialist Tillotts Pharma is looking to acquire further GI assets after its recent USD 200m M&A deal. The company is looking for assets which generate a turnover of EUR 50 – 150 million in Europe and/or Japan, and also to…

Taiwan Petar Vazharov, Alvogen’s executive vice president for Asia Pacific, and, Jefferson Wang, general manager of Lotus, provide insights into Lotus’ tremendous evolution from a local generics company into a regional player holding international ambitions, and highlight the main achievements of this fast-growing company since it joined the Alvogen group in…

Taiwan The Chairman & CEO of TaiGen Biotechnology discusses the growth opportunities that the company holds in China, its main target market, and documents how her long-term strategic outlook made the company one of the most successful biotech companies in the region today, holding an unrivalled experience and unique positioning in…

Mexico Paulo de Resende, CEO of Laboratorios Grin-Lupin in Mexico, describes the current state of the Mexican pharmaceutical market and explains how the acquisition of Laboratorios Grin will help increase Lupin’s footprint in Latin America by bringing more expertise and R&D resources. Could you please introduce yourself to our international audience…